



Europass Curriculum Vitae

Personal information

First name(s) / Surname(s) **Laura Mercatali**

Occupational field **Researcher in translational oncology**

Work experiences

Dates	01/2008→
Occupation or position held	Senior Researcher; Lab referent for Osteoncology and rare Tumors
Main activities and responsibilities	Laboratory biologist. Main activities: cell cultures, western blot, RT-PCR, RNA and DNA extraction. Article drafting and editing. Conceiving of translational studies. Projects topic: translational research in osteoncology
Name and address of employer	Osteoncology and rare Tumors center, IRCCS Istituto scientifico romagnolo per lo studio e la cura dei tumori (IRST), 40, Piero Maroncelli rd, 47014 Meldola (FC) Italy
Type of business or sector	Translational research and support to clinical diagnostic
Dates	1/2003-12/2007
Occupation or position held	Junior Researcher
Main activities and responsibilities	Laboratory biologist. Main activities: cell cultures, western blot, RT-PCR, RNA and DNA extraction. Article drafting and editing. Conceiving of translational studies. Projects topic: translational research in osteoncology
Name and address of employer	Osteoncology and rare Tumors center, IRCCS Istituto scientifico romagnolo per lo studio e la cura dei tumori (IRST), 40, Piero Maroncelli rd, 47014 Meldola (FC) Italy
Type of business or sector	Translational research and support to clinical diagnostic
Dates	03/2002-12/2002
Occupation or position held	Voluntary worker
Main activities and responsibilities	Laboratory biologist. Main activities: DNA extraction, RT-PCR, database implementation.
Name and address of employer	Bioscience Laboratory, Ospedale Pierantoni, Via Forlanini 34 Forli (FC), Italy
Type of business or sector	Translational research and support to clinical diagnostic
Dates	01/2002 - 07/2002
Occupation or position held	Researcher in experimental oncology
Main activities and responsibilities	Laboratory biologist. Main activities: cell coltures, preclinical tests Project topic: Cell-cycle deregulation in BALB/c 3T3 cells transformed by 1,2-dibromoethane and folpet pesticides.
Name and address of employer	Istituto di Cancerologia, Università di Bologna Via filopanti, Bologna (Italy)
Type of business or sector	Scientific research

Education and training

Dates 2014
 Type of qualification awarded PHD
 Principal subjects Pharmacology, Oncology
 Name and type of organisation providing education and training Alma mater studiorum, Bologna University, Pharmacology Faculty

Dates 2013 jun-set
 Title of qualification awarded VSRC at Princeton University
 Principal subjects/occupational skills covered
 Name and type of organisation providing education and training

Dates 2003-2005
 Title of qualification awarded MSC in toxicology (pharmaceutical curriculum) (maximum votation)
 Principal subjects/occupational skills covered Toxicology, Pharmacology, Cancerogenesis process
 Name and type of organisation providing education and training Alma mater studiorum, Bologna University, Pharmacology Faculty
 Level in national or international classification

Dates 10/1996 - 12/2001
 Title of qualification awarded Master Degree in Biomolecular biology
 Principal subjects/occupational skills covered English language, cellular and molecular biology, Oncology, data analysis,
 Name and type of organisation providing education and training Bologna University, Faculty of Bioscience
 Level in national or international classification Second level Degree/ Specialistic Degree

Personal skills and competences

Mother tongue(s) **Italian**

Other language(s)

Self-assessment

European level (*)

English

Understanding				Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production			
B2	Independent user	B2	Independent user	B2	Independent user	B2	Independent user	B2	Independent user

(*) [Common European Framework of Reference for Languages](#)

Social skills and competences Able to work whit a group of people on a team, especially in laboratory where is required collaboration between different professional figures

Technical skills and competences Good knowledge of laboratory techniques in particular cells cultures, western blot, PCR, DNA and RNA extraction and basic knowledge of citometry

Computer skills and competences Good knowledge of Office packet, in particular word and excel. Basic Knowledge of statistical analysis programs, as SPSS and GraphPad

Driving licence	Car driving licence
Honor and award	<p>2012: win a travel grant of 400\$ for an abstract sent to IBCD 2012 (IBMS)</p> <p>2013: Winner of Francesco Baracca Ward as a I RST researcher</p> <p>2013: winner of Berluschi Prize for young researcher</p>
Publications	<p>More than 20 abstract accepted as a poster at national- International Oncology meeting as first author</p> <p>Papers</p>

- 1) Bongiovanni A, Ricci M, Riva N, Calpona S, Oboldi D, Pieri F, Cavaliere D, Mercatali L, Liverani C, La Manna F, De Vita A, Foca F, Gunelli E, Amadori D, Ibrahim T. Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report. *Future Oncol.* 2014 Dec;10(15):2423-7. doi: 10.2217/fon.14.159.
- 2) Bongiovanni A, Riva N, Calpona S, Ricci M, Gunelli E, Liverani C, La Manna F, De Vita A, Monti M, Severi S, Pieri F, Amadori E, Galassi R, Cavaliere D, Zaccaroni A, Tartaglia A, Lunedei V, Gardini A, Mercatali L, Amadori D, Ibrahim T. Metronomic capecitabine in gastroenteropancreatic neuroendocrine tumors: a suitable regimen and review of the literature. *Onco Targets Ther.* 2014 Oct 20;7:1919-26
- 3) Ricci M, Amadori E, Chiesa F, Bongiovanni A, Liverani C, Fabbri L, Falasconi MC, Casadei R, Oboldi D, Galassi R, Micheletti S, Severi S, Serra L, Pieri F, Calabrese L, Riva N, Calpona S, Gunelli E, Mercatali L, Amadori D, Ibrahim T. Single bone metastasis from adenocarcinoma of the lacrimal gland: a case report. *Future Oncol.* 2014 Aug;10(10):1735-9.
- 4) Chakrabarti R, Wei Y, Hwang J, Hang X, Andres Blanco M, Choudhury A, Tiede B, Romano RA, DeCoste C, Mercatali L, Ibrahim T, Amadori D, Kannan N, Eaves CJ, Sinha S, Kang Y. ΔNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. *Nat Cell Biol.* 2014 Oct;16(10):1004-15, 1-13.
- 5) Ell B, Qiu Q, Wei Y, Mercatali L, Ibrahim T, Amadori D, Kang Y. The microRNA-23b/27b/24 cluster promotes breast cancer lung metastasis by targeting metastasis-suppressive gene prosaposin. *J Biol Chem.* 2014 Aug 8;289(32):21888-95.
- 6) Liverani C, Mercatali L, Spadazzi C, La Manna F, De Vita A, Riva N, Calpona S, Ricci M, Bongiovanni A, Gunelli E, Zanoni M, Fabbri F, Zoli W, Amadori D, Ibrahim T. CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems. *Bone.* 2014 Sep;66:214-22.
- 7) Ell B, Mercatali L, Ibrahim T, Campbell N, Schwarzenbach H, Pantel K, Amadori D, Kang Y. Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. *Cancer Cell.* 2013 Oct 14;24(4):542-56. doi: 10.1016/j.ccr.2013.09.008.
- 8) Ibrahim T, Mercatali L, Amadori D. Bone and cancer: the osteoncology. *Clin Cases Miner Bone Metab.* 2013 May;10(2):121-123.
- 9) Ibrahim T, Mercatali L, Amadori D. A new emergency in oncology: Bone metastases in breast cancer patients (Review). *Oncol Lett.* 2013 Aug;6(2):306-310. Epub 2013 Jun 4
- 10) Amadori D, Mercatali L, Nanni O, Aglietta M, Alessi B, Gianni L, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI, Ibrahim T. What can we learn from the ZOOM trial? - Authors' reply. *Lancet Oncol.* 2013 Sep;14(10):e388-90.
- 11) Mercatali L, Ricci M, Scarpi E, Serra P, Fabbri F, Ricci R, Liverani C, Zanoni M, Zoli W, Maltoni R, Gunelli E, Amadori D, Ibrahim T. RANK/RANK-L/OPG in Patients with Bone Metastases Treated with Anticancer Agents and Zoledronic Acid: A Prospective Study. *Int J Mol Sci.* 2013 May 23;14(6):10683-93.
- 12) Ibrahim T, Farolfi A, Mercatali L, Ricci M, Amadori D. Metastatic bone disease in the era of bone-targeted therapy: clinical impact. *Tumori.* 2013 Jan-Feb;99(1):1-9. Review.
- 13) Ulivi P, Mercatali L, Casoni GL, Scarpi E, Bucchi L, Silvestrini R, Sanna S, Monteverde M, Amadori D, Poletti V, Zoli W. Multiple marker detection in peripheral blood for NSCLC diagnosis. *PLoS One.* 2013;8(2):e57401.
- 14) Ibrahim T, Liverani C, Mercatali L, Sacanna E, Zanoni M, Fabbri F, Zoli W, Amadori D. Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines. *Int J Oncol.* 2013 Apr;42(4):1263-70.
- 15) Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y, Li C, Chong M, Ibrahim T, Mercatali L, Amadori D, Lu X, Xie D, Li QJ, Wang XF. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. *Nat Cell Biol.* 2013
- 16) Ibrahim T, Farolfi A, Scarpi E, Mercatali L, Medri L, Ricci M, Nanni O, Serra L, Amadori D. Hormonal Receptor, Human Epidermal Growth Factor Receptor-2, and Ki67 Discordance between Primary Breast Cancer and Paired Metastases: Clinical Impact. *Oncology.* 2013;84(3):150-7.
- 17) Ibrahim T, Mercatali L, Sacanna E, Tesei A, Carloni S, Ulivi P, Liverani C, Fabbri F, Zanoni M, Zoli W, Amadori D. Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. *Cancer Cell Int.* 2012 Nov 22;12(1):48
- 18) Chakrabarti R, Hwang J, Andres Blanco M, Wei Y, Lukačičin M, Romano RA, Smalley K, Liu S, Yang Q, Ibrahim T, Mercatali L, Amadori D, Haffty BG, Sinha S, Kang Y. E1f5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. *Nat Cell Biol.* 2012 Nov;14(11):1212-22
- 19) Korpál M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, Wei Y, Hu G, Garcia BA, Ragoussis J, Amadori D, Harris AL, Kang Y. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. *Nat Med.* 2011 Aug 7;17(8):1101-8.
- 20) Ibrahim T, Sacanna E, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Ricci R, Serra L, Kang Y, Amadori D. Clin Breast Cancer Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients. *Ibrahim T, Sacanna.* 2011 Dec;11(6):369-75.
- 21) Sacanna E, Ibrahim T, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Brovaccini S, Ricci R

- 27) Ibrahim T, Barbanti F, Giorgio-Marrano G, Mercatali L, Ronconi S, Vicini C, Amadori D. Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study. *Oncologist*. 2008 Mar;13(3):330-6.
- 28) Ibrahim T, Flamini E, Fabbri L, Serra P, Mercatali L, Ricci R, Sacanna E, Falasconi MC, Casadei R, Galassi R, Giannini M, Bazzocchi O, Calzolari F, Nunziatini R, Gaudio M, Maltoni M, Amadori D. Multidisciplinary approach to the treatment of bone metastases: Osteo-Oncology Center, a new organizational model. *Tumori*. 2009 May-Jun;95(3):291-7.
- 29) Flamini E, Mercatali L, Nanni O, Calistri D, Nunziatini R, Zoli W, Rosetti P, Gardini N, Lattuneddu A, Verdecchia GM, Amadori D. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. *Clin Cancer Res*. 2006 Dec 1;12(23):6985-8
- 30) Mercatali L, Valenti V, Calistri D, Calpona S, Rosti G, Folli S, Gaudio M, Frassinetti GL, Amadori D, Flamini E. RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients. *Ann Oncol*. 2006 Mar;17(3):424-8.
- 31) Santucci MA, Mercatali L, Brusa G, Pattacini L, Barbieri E, Perocco P. Cell-cycle deregulation in BALB/c 3T3 cells transformed by 1,2-dibromoethane and folpet pesticides. *Environ Mol Mutagen*. 2003;41(5):315-21.
- 32) Barbieri L, Brigotti M, Perocco P, Carnicelli D, Ciani M, Mercatali L, Stirpe F. Ribosome-inactivating proteins depurinate poly(ADP-ribosyl)ated poly(ADP-ribose) polymerase and have transforming activity for 3T3 fibroblasts. *FEBS Lett*. 2003 Mar 13;

Some other papers are in press

Bongiovanni A, Ricci M, Riva N, Calpona S, Oboldi D, Pieri F, Cavaliere D, Mercatali L, Liverani C, La Manna F, De Vita A, Foca F, Gunelli E, Amadori D, Ibrahim T. Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report. *Future Oncol*. 2014 Dec;10(15):2423-7. doi: 10.2217/fon.14.159.

Bongiovanni A, Riva N, Calpona S, Ricci M, Gunelli E, Liverani C, La Manna F, De Vita A, Monti M, Severi S, Pieri F, Amadori E, Galassi R, Cavaliere D, Zaccaroni A, Tartaglia A, Lunedei V, Gardini A, Mercatali L, Amadori D, Ibrahim T. Metronomic capecitabine in gastroenteropancreatic neuroendocrine tumors: a suitable regimen and review of the literature. *Onco Targets Ther*. 2014 Oct 20;7:1919-26. doi: 10.2147/OTT.S68573. eCollection 2014.

Ricci M, Amadori E, Chiesa F, Bongiovanni A, Liverani C, Fabbri L, Falasconi MC, Casadei R, Oboldi D, Galassi R, Micheletti S, Severi S, Serra L, Pieri F, Calabrese L, Riva N, Calpona S, Gunelli E, Mercatali L, Amadori D, Ibrahim T. Single bone metastasis from adenocarcinoma of the lacrimal gland: a case report. *Future Oncol*. 2014 Aug;10(10):1735-9. doi: 10.2217/fon.14.36.

Chakrabarti R, Wei Y, Hwang J, Hang X, Andres Blanco M, Choudhury A, Tiede B, Romano RA, DeCoste C, Mercatali L, Ibrahim T, Amadori D, Kannan N, Eaves CJ, Sinha S, Kang Y. Δ Np63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. *Nat Cell Biol*. 2014 Oct;16(10):1004-15. doi: 10.1038/ncb3040. Epub 2014 Sep 21.

El B, Qiu Q, Wei Y, Mercatali L, Ibrahim T, Amadori D, Kang Y. The microRNA-23b/27b/24 cluster promotes breast cancer lung metastasis by targeting metastasis-suppressive gene prosaposin. *J Biol Chem*. 2014 Aug 8;289(32):21888-95.

Liverani C, Mercatali L, Spadazzi C, La Manna F, De Vita A, Riva N, Calpona S, Ricci M, Bongiovanni A, Gunelli E, Zanoni M, Fabbri F, Zoli W, Amadori D, Ibrahim T. CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems. *Bone*. 2014 Sep;66:214-22.